Financial support: The study was funded by GlaxoSmithKline (GSK).
Revisiting the Efficacy of Sumatriptan Therapy During the Aura Phase of Migraine
Article first published online: 28 APR 2009
© 2009 the Authors. Journal compilation © 2009 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 49, Issue 7, pages 1001–1004, July/August 2009
How to Cite
Aurora, S. K., Barrodale, P. M., McDonald, S. A., Jakubowski, M. and Burstein, R. (2009), Revisiting the Efficacy of Sumatriptan Therapy During the Aura Phase of Migraine. Headache: The Journal of Head and Face Pain, 49: 1001–1004. doi: 10.1111/j.1526-4610.2009.01429.x
Conflict of Interest: Dr. Aurora serves as a consultant to GSK. Dr. Burstein received grant support for basic research studies from GSK. Dr. MacDonald is an employee of GSK.
- Issue published online: 6 JUL 2009
- Article first published online: 28 APR 2009
- Accepted for publication March 8, 2009.
- central sensitization;
Objective.— To reexamine the efficacy of terminating migraine headache by administration of sumatriptan during the visual-aura phase of the attack.
Background.— Although the antimigraine action of triptans is most effective soon after onset of the headache, treatment during the aura phase has been found to be ineffective.
Methods.— Nineteen subjects having migraine with aura were studied using a 4-way crossover, open-label design. Each patient was asked to treat 8 consecutive attacks with 100 mg of sumatriptan RT: 3 attacks treated at a timing of the patient's discretion (baseline); 1 attack treated 4 hours after onset of pain (late); 2 attacks treated within 1 hour of onset of pain (early); 2 attacks treated during the aura phase – before the onset of pain (aura). Pain level and cutaneous allodynia were reported by the patients at the onset of pain, at the time of treatment, and 2 and 24 hours after treatment.
Results.— Sumatriptan treatment during the aura preempted the development of headache in 34/38 (89%) attacks. The same patients were rendered pain-free in 30/38 (79%) of attacks treated within 1 hour of pain onset, and in 4/19 (21%) of attacks treated 4 hours after the onset of pain. The incidence of allodynia at the time of treatment was 2/38 (5%) in attacks treated during aura, 8/38 (21%) in attacks treated early, and 14/19 (74%) in attacks treated late.
Conclusion.— Considering the discrepancy between the present and previous clinical studies, it is worthwhile revisiting the efficacy of preemptive triptan therapy during the aura phase of migraine attacks, using larger-scale, 3-way, crossover, placebo-controlled studies.